DEVELOPMENT JOURNEY TO REPLACE NEURONS LOST TO ALZHEIMER’S DISEASE WITH NEURAL PRECURSOR CELLS DERIVED FROM SKIN CELLS
With
Professor Michael Valenzuela,
Founder and Chief Scientific Officer,
Skin2Neuron
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
He studied psychology at the University of New South Wales (UNSW) before completing a PhD on Cognitive Reserve. This work was recognised by one of the nation’s top awards, the Australian Museum Eureka Prize for Medical Research.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
Between 2019-2021 he was employed as a senior advisor to the WHO in one of its flagship Decade of Healthy Ageing initiatives. He also joined the Centre for Healthy Brain Ageing at UNSW as Visiting Professor and played a leading role in the design and successful completion of the Maintain Your Brain – the world’s largest dementia prevention trial that found it is possible to delay cognitive decline in older at-risk people by about 1-year.
Professor Valenzuela is a frequent media commentator and author of the popular science book Maintain Your Brain.
Source: Supplied
You Might also like
-
A clinical research career working Sponsor-side, CRO-side to Site-side
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
-
Integrating oral health care across non-dental professionals
Poor oral health can contribute to or exacerbate several systemic health conditions due to the close connection between oral bacteria, inflammation, and systemic processes. These conditions include cardiovascular health, diabetes, respiratory health, cognitive health, pregnancy and birth outcomes.
-
Psychiatrists to discuss connectedness at RANZCP 2023 Congress
Next week, at the Perth Convention and Exhibition Centre, The Royal Australian and New Zealand College of Psychiatrists (RANZCP) meet for the RANZCP 2023 Congress on the theme of “New Horizons: Connected Futures”
Australian Health Journal spoke to current President-Elect Dr Elizabeth Moore and soon to be President, RANZCP about the Congress, as well as the recent Federal Budget announcements around mental health funding.